Lapsi Health, a Dutch-American health technology company, has joined forces with eMurmur, a Canadian-Austrian leader in AI for cardiac and pulmonary auscultation, to integrate eMurmur’s Heart AI algorithms into Keikku 2.0, the first FDA-cleared smart stethoscope with an AI-powered scribe. This collaboration aims to enhance diagnostic accuracy and improve clinical workflow by combining eMurmur’s validated murmur detection algorithms, which show 90 percent sensitivity and specificity, with Keikku 2.0’s advanced multimodal platform. Clinicians will now be able to perform expert-level cardiac exams while automatically capturing patient encounter details through AI-driven transcription, transforming how patient consultations are conducted.
Health Technology Insights: Volpara Rebrands as Lunit to Advance AI Cancer Solutions
“Working together is essential for meaningful innovation, and this partnership reflects that philosophy,” said Jhonatan Bringas Dimitriades, MD, CEO and Co-Founder of Lapsi Health. “Integrating Keikku’s smart hardware and AI scribe with eMurmur’s cardiac analytics creates one of the most advanced medical tools available to clinicians today.”
Andreas Schriefl, PhD, Founder and CEO of eMurmur, said, “Adding our AI to Keikku equips healthcare providers with a critical tool across all care environments. From primary care to cardiology, telemedicine to hospital rounds, and pediatrics to adults, this integration delivers precise diagnostic insights where they are most needed.”
Health Technology Insights: THINK Surgical appoints Josh DeRienzis as Chief Legal Officer
Diana van Stijn, MD, PhD, Chief Medical Officer and Co-Founder of Lapsi Health, added, “Connecting eMurmur’s algorithms to Keikku allows physicians to maximize what they achieve during each patient visit. The integration ensures the highest-quality cardiac assessments can be performed in real time.”
The partnership combines Lapsi Health’s expertise in medical device design and AI implementation with eMurmur’s clinically validated auscultation analytics, including trials conducted at Johns Hopkins University. The AI is FDA-cleared, CE-marked, and compatible with multiple hardware devices. Keikku 2.0 users will receive the integrated solution via a software update with no new hardware required. Providers in primary care, cardiology, pediatrics, and emergency medicine will gain access to cardiologist-level auscultation insights, enabling earlier detection of structural heart conditions and better clinical decision-making.
Health Technology Insights: Lilly and US Government Agree to Expand Access to Obesity Medicines to Millions of Americans
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
